Business Wire

KVANTO-PAYMENT-SOLUTIONS

Share
Kvanto Announces NEW Edge Partnership World Wide EU

For Pure Health inc. (FPH) has signed a partnership agreement with Kvanto Payment Services A/S (hereafter Kvanto). FPH provides sales all over the globe. All numbers and assumptions are based on previous first-hand experience with similar setups and products. And has made it before and they have entered with Kvanto and using the Payment Gateway, this has a large opportunity.

“FPH was looking for a partner to handle payments solution. One of the most important things for FPH is that customers experience has a smooth and secure checkout when buying our products from our website.

Kvanto Payment services not only provided us with this solution but also helped us set up the system, quickly and seamlessly. Furthermore, FPH has trusted Kvanto Payment Services with helping FPH with administration, technical, and development.

This special cooperation we have not been able to find elsewhere. From the start of this cooperation, we have made this as a focus development case, and we are now moving it to a slot of large opportunities of 250M € turnover a year and our aim is larger, and Kvanto stands the challenge and we have been satisfying so fare.

Allan Djurhuus
CEO, FPH Inc
.”

Benefits compared to other solution partners

Kvanto has an MPI security Solution, it works outside Europe, and that’s where we have most of the clients in FPH. Kvanto makes sure the merchant’s customer and the cardholder are the same person by sending a code to the customer's cell phone, which the customer must fill into the payment window before the payment is approved.

FPH has made this happen, through our marketing corporation with Konnektive CRM in US/PR and we have worked with Konnektive CRM for years now, and it has been a huge success, and we are so delighted to manage to get both Kvanto and Konnektive CRM together, and we have now one solution, and that saves us a large amount of time and money, we can´s understand why people not are managing this as it has to be, and as Konnektive is saying.

“Time is money.
With hundreds of integrations through Konnektive, you’ll never be scrambling to find your data by going to multiple systems. We put everything you need at your fingertips; all in one place!

Konnektive CRM was designed to Automate and Synchronize Your Entire Business with the easiest, most intuitive user interface.
Brian Bolerjack,
Konnektive CRM”

Kvanto cooperation with both the system provider and customer

Kvanto has made an option and an opportunity by creating this cooperation, to manage a whole platform, by offering the Kvanto ESB Payment Gateway, and support the individual customer and the whole group of Konnektive CRM platform solution, as a trusted partner. Kvanto has proved to be highlighted as a service provider that can handle payment transactions across the payment ECO-system, and even if you are making the payment happen in Europe or elsewhere, we can carry the solution to a new level of security by Kvanto MPI solution.

Value proposition

By managing this, and through the Kvanto Gateway Solution, it will be possible to draw more potential clients into our merchants, and our expectation of this cooperation is more than 12 Mill $ in turnover a year, on this case alone.

And the options for new clients is much higher, and we can multiply this 3-4 times.

This is an optimizing way of creating new clients, and we have today two new clients, that bring more merchants in through this cooperation, and we expect to reach some 15-22 clients with the support we have from Konnektive CRM staff and PR from FPH.

About Kvanto Payment Solutions

Kvanto is a Payment Solution Provider company that provides simple, flexible, and cost-efficient payment solutions on the global market. Through experience and knowledge does Kvanto challenge current structures and procedures in the established market.

Kvanto strives to be a one-stop-shop for payments with cross border solutions for merchants and the leading EMEA/APAC multi-connectivity payment solutions provider measured in processing volume while being profitable.

For further investor enquires
Listing Partners LLC
support@listingpartners.lu

All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Kvanto Payment Systems A/S is under no obligation to (and expressly disclaim any such obligation to) update or alters our forward-looking statements, whether as a result of new information, future events, or otherwise.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon

Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release

The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered

TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents

AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release

Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce

ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release

Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye